Biodegradable gelatin-aminodextran particle coatings of and processes for making same

Claim 2

Colloidal particles having a plurality of pendent functional groups on an exterior coating of aminodextran in which each particle comprises a solid metallic core coated with a first gelatin layer of type B, alkali cured gelatin of Bloom in the range 60 to 225 and a second layer of an aminodextran, said layers having been either (a) crosslinked by the action of a chemical crosslinking agent or (b) joined by a condensation reaction between said gelatin and said aminodextran, such that said so layered particles can be stored as predominantly discrete colloidal particles having pendent functional groups.

Claim 3

Particles in accordance with claim 1 wherein said solid core consists of a magnetic particle having a hydrophobic surface.

Claim 4

Particles in accordance with claim 1 wherein said solid core is in the size range of 0.1 to 5.0 microns.

Claim 5

Particles in accordance with claim 1 wherein said solid core is in the size range of approximately 0.1 to 1.0 microns.

Claim 6

Particles in accordance with claim 1 or 2 wherein said chemical crosslinking agent is glutaraldehyde.

Claim 7

Particles in accordance with claim 1 or 2 wherein said functional groups are amino groups.

Claim 8

Particles in accordance with claim 1 or 2 wherein said functional groups are selected from the group consisting of maleimidyl groups and sulfhydryl groups.

Claim 9

Particles in accordance with claim 7 wherein a biological substance is bound to either of said maleimidyl groups and sulfhydryl groups.

Claim 10

Particles in accordance with claim 8 wherein said biological substance is selected from the group consisting of polyclonal antibodies and monoclonal antibodies.

Claim 11

Particles in accordance with claim 8 wherein said biological substance has reactive substituents selected from the group consisting of sulfhydryl substituents and maleimidyl substituents, and further provided that when the particle functional group is maleimidyl, the biological substitutent is sulfhydryl and when the particle functional group is sulfhydryl, the biological substance substituent is maleimidyl.

Claim 12

Particles in accordance with claim 9 wherein said antibodies have reactive sulfhydryl or maleimidyl substituents.

Claim 13

Particles in accordance with claim 1 wherein said functional groups comprise biological substances bonded to said gelatin/aminodextran coated core.

Claim 14

Particles in accordance with claim 12 wherein said biological substances are selected from the groups consisting of polyclonal antibodies and monoclonal antibodies.

Claim 15

Particles in accordance with claim 1 wherein said functional groups are polyclonal antibodies.

Claim 16

Particles in accordance with claim 1 wherein said functional groups are monoclonal antibodies.

Claim 17

A process for preparing discrete colloidal particles having a plurality of pendent functional groups on an exterior coating of aminodextran in which each particle comprises a solid metallic core coated either with biodegrable, crosslinked or condensed layers of type B, alkali cured gelatin of Bloom 60 to 225 and an aminodextran, said process comprising; (a) (i) (1) preparing metallic core particles in said gelatin or (2) adsorbing as a first layer said gelatin onto said metallic core particles and adsorbing as a second layer an aminodextran onto the surface of the gelatin coated particles; (ii) crosslinking the coating of step (a) (i) by reaction with a chemical crosslinking agent; and (iii) blocking free, unreacted crosslinking agent functional groups present on the surface of the product of step (a) (ii) by reaction of said groups with a sufficient amount of a polyamine such that one of the amine --NH 2 groups reacts with said unreacted crosslinking agent functional group and the other NH 2 group or groups remain unreacted; or (b) (1) preparing metallic core particles in said gelatin or (2) adsorbing as a first layer said gelatin onto said metallic core particles and joining to said gelatin by a condensation reaction an aminodextran as a second layer; and (c) separating the coated particles of steps (a) and (b), washing the same and, if desired, derivatizing said particles by reaction with a bifunctional bridging reagent to obtain colloidal particles having additional pendent functional groups.

Claim 18

A process for preparing discrete colloidal particles having a plurality of pendent functional groups on an exterior coating of aminodextran in which each particle comprises a solid metallic core coated either with biodegrable, crosslinked or condensed layers of type B, alkali cured gelatin of Bloom 60 to 225 and an aminodextran, said process comprising; (a) (i) (1) preparing metallic core particles in said gelatin or (2) adsorbing as a first layer said gelatin onto said metallic core particles and adsorbing as a second layer an aminodextran onto the surface of the gelatin coated particles; (ii) crosslinking the coating of step (a) (i) by reaction with a chemical crosslinking agent; and (iii) blocking free, unreacted crosslinking agent functional groups present on the surface of the product of step (a) (ii) by reaction of said groups with a sufficient amount of a polyamine such that one of the amine --NH 2 groups reacts with said unreacted crosslinking agent functional group and the other NH 2 group or groups remain unreacted; or (b) (1) preparing metallic core particles in said gelatin or (2) adsorbing as a first layer said gelatin onto said metallic core particles and joining to said gelatin by a condensation reaction an aminodextran as a second layer; and (c) separating the coated particles of steps (a) and (b), washing the same and, if desired, derivatizing said particles by reaction with a bifunctional bridging reagent to obtain colloidal particles having additional pendent functional groups.

Claim 19

The process according to claim 16 wherein said solid core particles consist of magnetic particles having a hydrophobic surface.

Claim 20

The process in accordance with claim 16 wherein said core particles are in the size range of approximately 0.1 to 5.0 microns.

Claim 21

The process in accordance with claim 16 wherein said core particles are in the size range of approximately 0.1 to 1.0 microns.

Claim 22

The process in accordance with claim 16 or 17 wherein the chemical crosslinking agent is glutaraldehyde.

Claim 23

The process in accordance with claim 16 or 17 wherein said polyamine is selected from the group consisting of ethylenediamine, 1,3-diaminopropane, 1,4-cyclohexanediamine, 1,4-cyclohexenediamine, 1,4-phenylenediamine, diethylene triamine, and aminodextrans.

Claim 24

The process in accordance with claim 16 or 17 wherein the polyamine is selected from the group consisting of ethylenediamine and aminodextrans.

Claim 25

The process in accordance with claim 16 or 17 wherein said functional groups are selected from the group consisting of maleimidyl groups and sulfhydryl groups.

Claim 26

The process in accordance with claim 16 or 17 wherein said functional groups are biological substances attached to the product of step (c) and selected from the group consisting of biological substances having or derivatized to have reactive sulfhydryl or maleimidyl substituents.

Claim 27

The process in accordance with claim 24 wherein said biological substances are selected from the group consisting of polyclonal antibodies and monoclonal antibodies.

Claim 28

Particles with a polyclonal and/or monoclonal antibody covalently bonded thereto, each of said particles comprising: (a) a colloidal sized solid metallic core material; (b) (i) a first gelatin coating and a second aminodextran coating on the surface of said solid core and crosslinked thereon by a chemical crosslinking agent, or (ii) a first gelatin coating adsorbed onto the surface of said solid core and a second aminodextran coating joined to said gelatin coating by a condensation reaction, wherein said gelatin coating consists of a type B, alkali cured gelatin of Bloom in the range 60 to 225; (c) an antibody; and (d) a bridging group having an end covalently bonded to said aminodextran and another end covalently bonded to said antibody.

Claim 29

Particles with a polyclonal and/or monoclonal antibody covalently bonded thereto, each of said particles comprising: (a) a colloidal sized solid metallic core material; (b) (i) a first gelatin coating and a second aminodextran coating on the surface of said solid core and crosslinked thereon by a chemical crosslinking agent, or (ii) a first gelatin coating adsorbed onto the surface of said solid core and a second aminodextran coating joined to said gelatin coating by a condensation reaction, wherein said gelatin coating consists of a type B, alkali cured gelatin of Bloom in the range 60 to 225; (c) an antibody; and (d) a bridging group having an end covalently bonded to said aminodextran and another end covalently bonded to said antibody.

Claim 30

Particles in accordance with claim 26 wherein said solid core consists of magnetic particles having a hydrophobic surface.

Claim 31

Particles in accordance with claim 26 wherein said solid core material is in the size range of approximately 0.1 to 5.0 microns.

Claim 32

Particles in accordance with claim 26 wherein said solid core material is in the size range of 0.1 to 1.0 microns.

Claim 33

Particles in accordance with claim 26 or 27 wherein said crosslinking agent is glutaraldehyde.

Claim 34

Particles in accordance with claim 26 or 27 wherein said bridging group contains a polyamine having an amine group bonded to said crosslinked gelatin surface and another amine group or groups bonded to a moiety having a reactive maleimidyl or sulfhydryl group, said polyamine being selected from the group consisting of ethylenediamine, 1,3-diaminopropane, 1,4-cyclohexanediamine, 1,4-cyclohexenediamine, 1,4-phenylenediamine and diethylene triamine and aminodextrans.

Claim 35

The particles in accordance with claim 26 or 27 wherein said polyamines are ethylenediamine and aminodextrans.

Claim 36

The particles of claim 26 or 27 wherein said antibody has a reactive substituents selected from the group consisting of a sulfhydryl substituent and a maleimidyl substitutent, said sulfhydryl substituent being naturally present on said antibody or being generated by modification of an amino group or groups naturally present on said antibody with 2-iminothiolane hydrochloride, and said maleimidyl substituent be present by modification of an amino group or groups on said antibody with a maleimidyl containing reagent.

Claim 37

A process for preparing particles with a polyclonal and/or monoclonal antibody bound thereto, said process comprising: (I) (a) (1) preparing metallic core particles in type B, alkali cured gelatin of Bloom in the range 60 to 225, or (2) coating a preformed solid metallic core material with gelatin by mixing said core material with a 1% w/v aqueous solution of said gelatin, and (3) isolating and washing said particles of (1) or (2) with a solution of an aminodextran solution; (b) storing the washed particles of step (a) in suspension in an aqueous aminodextran solution until used in step (c), a time in the range of up to about six months, or immediately using the particles of step (a) in step (c); (c) suspending the particles of step (a) or the stored and subsequently separated particles of step (b) in an aminodextran coating solution; (d) mixing the suspension of step (c) with a solution of glutaraldehyde for a time in the range of about 1 hour, thereby crosslinking the surface adsorbed gelatin/aminodextran; (e) adding ethylenediamine to the suspension of step (d) and mixing the new suspension for a time in the range of 1 to 4 hours; (f) adding NaBH 4 to the suspension step of (e) and mixing the new suspension; (g) separating the particles of step (f) from the suspending solution and washing the particles with 0.2M aqueous NaCl; (h) reacting, with mixing, the resultant particles of step (f) or (g) with ethylenediamine in 0.2M NaCl aqueous solution containing 1-ethyl-3-(3-diamethylaminopropyl)-carbodiimide at ambient temperature; (i) separating the particles of step (h) from the reaction solution and washing them with phosphate buffered saline solution; (j) reacting the particles of step (i) with a bifunctional bridging reagent in phosphate buffered saline solution at ambient temperature for a time in the range of approximately 0.50 to 1.5 hours to prepare particles having reactive terminal maleimidyl or sulfhydryl groups bound to the particles' surface; and (k) separating the particles of step (j) and washing them with phosphate buffered saline solution; (II) separately preparing an antibody for conjugation to the particles of step (I)(k) by generating reactive substituents consisting of sulfhydryl groups or maleimidyl groups on said antibody; (III) reacting the particles of step (I)(k) and the antibody of step (II), with mixing, for a time in the range of about 1-3 hours, whereby said reactive substituents of said antibody are coupled to the particles' reactive groups, separating the resulting antibody containing particles from the reaction medium and washing them with buffered saline solution; (IV) blocking unreacted groups present on the product of step (III); and (V) separating and washing the antibody containing particles of step (IV) with about 1% bovine serum albumin in 0.1% NaN 3 in phosphate buffered saline solution, sorting the washed particles in said solution at about 4° C. for a period in the range of 8 to 16 hours, separating the antibody containing particles, again washing the particles with bovine serum albumin buffer solution, and storing the resulting antibody containing particles in about 1% bovine serum albumin, 0.1% NaN 3 in phosphate buffered saline solution until required for use.

Claim 38

A process for preparing particles with a polyclonal and/or monoclonal antibody bound thereto, said process comprising: (I) (a) (1) preparing metallic core particles in type B, alkali cured gelatin of Bloom in the range 60 to 225, or (2) coating a preformed solid metallic core material with gelatin by mixing said core material with a 1% w/v aqueous solution of said gelatin, and (3) isolating and washing said particles of (1) or (2) with a solution of an aminodextran solution; (b) storing the washed particles of step (a) in suspension in an aqueous aminodextran solution until used in step (c), a time in the range of up to about six months, or immediately using the particles of step (a) in step (c); (c) suspending the particles of step (a) or the stored and subsequently separated particles of step (b) in an aminodextran coating solution; (d) mixing the suspension of step (c) with a solution of glutaraldehyde for a time in the range of about 1 hour, thereby crosslinking the surface adsorbed gelatin/aminodextran; (e) adding ethylenediamine to the suspension of step (d) and mixing the new suspension for a time in the range of 1 to 4 hours; (f) adding NaBH 4 to the suspension step of (e) and mixing the new suspension; (g) separating the particles of step (f) from the suspending solution and washing the particles with 0.2M aqueous NaCl; (h) reacting, with mixing, the resultant particles of step (f) or (g) with ethylenediamine in 0.2M NaCl aqueous solution containing 1-ethyl-3-(3-diamethylaminopropyl)-carbodiimide at ambient temperature; (i) separating the particles of step (h) from the reaction solution and washing them with phosphate buffered saline solution; (j) reacting the particles of step (i) with a bifunctional bridging reagent in phosphate buffered saline solution at ambient temperature for a time in the range of approximately 0.50 to 1.5 hours to prepare particles having reactive terminal maleimidyl or sulfhydryl groups bound to the particles' surface; and (k) separating the particles of step (j) and washing them with phosphate buffered saline solution; (II) separately preparing an antibody for conjugation to the particles of step (I)(k) by generating reactive substituents consisting of sulfhydryl groups or maleimidyl groups on said antibody; (III) reacting the particles of step (I)(k) and the antibody of step (II), with mixing, for a time in the range of about 1-3 hours, whereby said reactive substituents of said antibody are coupled to the particles' reactive groups, separating the resulting antibody containing particles from the reaction medium and washing them with buffered saline solution; (IV) blocking unreacted groups present on the product of step (III); and (V) separating and washing the antibody containing particles of step (IV) with about 1% bovine serum albumin in 0.1% NaN 3 in phosphate buffered saline solution, sorting the washed particles in said solution at about 4° C. for a period in the range of 8 to 16 hours, separating the antibody containing particles, again washing the particles with bovine serum albumin buffer solution, and storing the resulting antibody containing particles in about 1% bovine serum albumin, 0.1% NaN 3 in phosphate buffered saline solution until required for use.

Claim 39

The process in accordance with claim 34 wherein said solid core material consists of a magnetic particle having a hydrophobic surface.

Claim 40

The process in accordance with claim 34 wherein said particles have a size of approximately 0.1 to 5.0 microns.

Claim 41

The process in accordance with claim 34 wherein said particles have a size of approximately 0.1 to 1.0 microns.

Claim 42

A process for preparing particles with a polyclonal and/or monoclonal antibody bound thereto, said process comprising: (I) (a) (1) preparing metallic core particles in type B, alkali cured gelatin of Bloom in the range 60 to 225, or (2) coating a preformed solid metallic core material with gelatin by mixing said core material with a 1% w/v aqueous solution said gelatin; (b) coating the particles of step (a) with an aminodextran through a condensation reaction between gelatin carboxylate groups and aminodextran amine groups; (c) separating the particles of step (b) from the reaction solution and washing them with phosphate buffered saline solution; (d) reacting the particles of step (c) with a bifunctional bridging reagent in phosphate buffered saline solution at ambient temperature for a time in the range of approximately 0.50 to 1.5 hours to prepare particles having reactive terminal maleimidyl or sulfhydryl groups bound to the particles' surface; and (II) separately preparing an antibody for conjunction to the particles of step (I)(d) by generating reactive substituents consisting of sulfhydryl groups or maleimidyl groups on said antibody; (III) reacting the particles of step (I)(d) and the antibody of step (II), with mixing, for a time in the range of about 1-3 hours, whereby said reactive substituents of said antibody are coupled to the particles' reactive groups separating the resulting antibody containing particles from the reaction medium and washing them with buffered saline solution; (IV) blocking unreacted groups present on the product of step (III); and (V) separating and washing the antibody containing particles of step (IV) with about 1% bovine serum albumin in 0.1% NaN 3 in phosphate buffered saline solution, storing the washed particles in said solution at about 4° C. for a period in the range of 8 to 16 hours, separating the antibody containing particles, again washing the particles with bovine serum albumin buffer solution, and storing the resulting antibody containing particles in about 1% bovine serum albumin, 0.1% NaN 3 in phosphate buffered saline solution until required for use.

Claim 43

A process for preparing particles with a polyclonal and/or monoclonal antibody bound thereto, said process comprising: (I) (a) (1) preparing metallic core particles in type B, alkali cured gelatin of Bloom in the range 60 to 225, or (2) coating a preformed solid metallic core material with gelatin by mixing said core material with a 1% w/v aqueous solution said gelatin; (b) coating the particles of step (a) with an aminodextran through a condensation reaction between gelatin carboxylate groups and aminodextran amine groups; (c) separating the particles of step (b) from the reaction solution and washing them with phosphate buffered saline solution; (d) reacting the particles of step (c) with a bifunctional bridging reagent in phosphate buffered saline solution at ambient temperature for a time in the range of approximately 0.50 to 1.5 hours to prepare particles having reactive terminal maleimidyl or sulfhydryl groups bound to the particles' surface; and (II) separately preparing an antibody for conjunction to the particles of step (I)(d) by generating reactive substituents consisting of sulfhydryl groups or maleimidyl groups on said antibody; (III) reacting the particles of step (I)(d) and the antibody of step (II), with mixing, for a time in the range of about 1-3 hours, whereby said reactive substituents of said antibody are coupled to the particles' reactive groups separating the resulting antibody containing particles from the reaction medium and washing them with buffered saline solution; (IV) blocking unreacted groups present on the product of step (III); and (V) separating and washing the antibody containing particles of step (IV) with about 1% bovine serum albumin in 0.1% NaN 3 in phosphate buffered saline solution, storing the washed particles in said solution at about 4° C. for a period in the range of 8 to 16 hours, separating the antibody containing particles, again washing the particles with bovine serum albumin buffer solution, and storing the resulting antibody containing particles in about 1% bovine serum albumin, 0.1% NaN 3 in phosphate buffered saline solution until required for use.

Claim 44

The process in accordance with claim 38 wherein said solid core material consists of a magnetic particle having a hydrophobic surface.

Claim 45

The process in accordance with claim 38 wherein said particles have a size of approximately 0.1 to 5.0 microns.

Claim 46

The process in accordance with claim 38 wherein said particles have a size of approximately 0.1 to 1.0 microns.